CURE - Oncology & Cancer News for Patients & Caregivers
Warmth, Friendship and Compassion in Cancer Care. December 31st 2024. Carla Chapman, a nurse at Dana-Farber Cancer Institute, is recognized for her unwavering support of patients, …
Transurethral Ultrasound Ablation a Promising Prostate Cancer …
2024年10月14日 · Patients with prostate cancer demonstrated reduced tumor volume and PSA levels, a key marker of prostate cancer progression, and experienced improved urinary …
Top FDA Approvals of Oncology Therapies in 2024
2024年12月23日 · Throughout 2024, the Food and Drug Administration (FDA) approved many cancer treatments, benefitting patients with different types of cancer. CURE compiled a list of …
TIL Therapy Uses the Body’s Own Cells to Attack Cancer Cells in …
2024年11月13日 · Key Takeaways. TIL therapy uses a patient's own T cells, expanded in vitro, to target cancer cells, offering a personalized treatment approach. Amtagvi (lifileucel) is the first …
Lymphedema Myths and Misconceptions, From Exercise to Blood …
2024年11月13日 · Key Takeaways. Lymphedema risk varies significantly by cancer type and lymph node removal extent, necessitating personalized risk assessments. Misconceptions …
6 FDA Cancer Approvals from August 2024 - Curetoday
In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.
FDA Approves Ensacove for ALK-Positive NSCLC
2024年12月18日 · Findings from the trial were published in JAMA Oncology in 2021, where Ensacove was found to result in what researchers described as a statistically significant …
Long-Term Study Data Support Keytruda as Standard of Care for …
2024年10月1日 · A 10-year follow-up data from the KEYNOTE-006 study showed that Keytruda continued to outperform Yervoy in terms of overall survival, progression-free survival, and …
Finding Hope With Antibody-Drug Conjugates in Managing Breast …
2024年12月5日 · Among Hamilton’s patients is Karen Broyles, 66, of northeastern Tennessee. Before receiving her diagnosis of HER2-positive breast cancer in 2007, she considered herself …
Looking Ahead After Kisqali’s FDA Approval for Adjuvant …
2024年12月10日 · Kisqali (ribociclib), a CDK4/6 inhibitor, has made significant strides in the treatment of HR-positive, HER2-negative early breast cancer, although several follow-up …